Evidence map›Paper›PMID 38687360›Full record

ArticlePsychopharmacology2024

Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.

Kimberly Sakai, Ellen R Bradley, Joseph A Zamaria, Gabrielle Agin-Liebes, D Parker Kelley, Alexander Fish, Valeria Martini, Michelle C Ferris, Emma Morton, Erin E Michalak and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Concomitant use of antidepressants and classic psychedelics: A scoping review.Journal of psychopharmacology (Oxford, England) · 2025
    Article
  6. Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice.The international journal of neuropsychopharmacology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kimberly Sakai *Department of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
Ellen R Bradley *Department of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA. Ellen.bradley@ucsf.edu.ORCID http://orcid.org/0000-0001-6787-1490
Joseph A ZamariaDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
Gabrielle Agin-LiebesDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
D Parker KelleyDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
Alexander FishDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
Valeria MartiniDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
Michelle C FerrisPsychology Department, Palo Alto University, Palo Alto, CA, 94304, USA.
Emma MortonDepartment of Psychiatry, University of British Columbia, Vancouver, BC, V6T 2A1, Canada.
Erin E MichalakDepartment of Psychiatry, University of British Columbia, Vancouver, BC, V6T 2A1, Canada.
Aoife O'DonovanDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.
Joshua D WoolleyDepartment of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA, 94143, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleTreatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin and SSRIs is critical for evaluating the safety, efficacy, and scalability of psilocybin-based treatments. Current knowledge about these interactions is limited, as most clinical psilocybin research has prohibited concomittant SSRI use.

objectivesWe aimed to explore potential interactions between psilocybin and SSRIs by characterizing peoples' real-world experiences using psilocybin mushrooms and SSRIs together.

methodsWe conducted a systematic search of Reddit for posts describing psilocybin mushroom and SSRI coadministration. We identified 443 eligible posts and applied qualitative content analysis to each.

results8% of posts reported negative physical or psychological effects resulting from coadministration. These included 13 reports that may reflect serotonin toxicity, and 1 concerning for a psychotic/manic episode. 54% of posts described reduced intensity of the acute psilocybin experience, but 39% reported unchanged intensity with SSRI coadministration.

conclusionsPsilocybin's interactions with SSRIs are likely complex and may depend on multiple factors. Prospective studies are needed to evaluate whether psilocybin treatments are reliably safe and effective in the setting of SSRI use.

Indexed as

AgaricalesDrug InteractionsHallucinogensPsilocybinSelective Serotonin Reuptake InhibitorsHumansHallucinogensPsilocybinSelective Serotonin Reuptake InhibitorsAntidepressantDrug-drug interactionsPsilocybinSerotonin

Identifiers

PMID38687360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.